Anti-CD274/PD-L1/B7-H1 Polyclonal Antibody (HV974014)

Datasheet Share product Copy info

Price(USD): $

Spec:

50ug
100ug

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.

HV974014

Description

Anti-CD274/PD-L1/B7-H1 Polyclonal Antibody (HV974014) is a rabbit polyclonal antibody detecting B7-H1 in ELISA, IHC, WB. Suitable for Human.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

Species reactivity

Human

Applications

ELISA, IHC, WB

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human CD274/PD-L1/B7-H1 (Phe19-Arg238).

Target

B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274

Purification

Purified by antigen affinity column.

Accession

Q9NZQ7

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443

2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410

3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417

4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419

5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298

6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077

7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201

Note

For research use only.

Images

Western blot

Western blot analysis was performed using anti-CD274/PD-L1/B7-H1 polyclonal antibody at 1ug/mL on recombinant CD274/PD-L1/B7-H1 (Catalog No. HV974012).

References

Datasheet